A Study to Evaluate the Efficacy and of Stillen Tab. and to Demonstrate the Non-inferiority of Stillen Tab.

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicenter, active-controlled, randomized, double-blinded, paralleled group clinical study to evaluate the efficacy of 4-week treatment with Stillen tab. in patients with acute or chronic gastritis. Subject will receive Stillen tab or Mucosta tab., three times a day for four weeks.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dong-A Pharmaceutical Co., Ltd.; Dong-A ST Co., Ltd.

Criteria

Inclusion Criteria:

• Age is over 20 years old, under 75 years old, men or women

• Patients diagnosed with acute or chronic gastritis by gastroscopy

• Patients with one or more erosions found by gastroscopy

• Signed the informed consent forms

Exclusion Criteria:

• Patients with peptic ulcer and gastroesophageal reflux disease

• Patients administered with prokinetics, H2 receptor antagonists, proton pump inhibitors, anticholinergic drugs or non-steroid anti-inflammatory drugs prior to study in 2 weeks

• Patients with surgery related to gastroesophageal

• Patients with Zollinger-Ellison syndrome

• Patients with any kind of malignant tumor

• Patients administered with anti-thrombotic drugs

• Patients with significant cardiovascular, pulmonary, heptic, renal, hemopoietic or endocrine system primary disease

• Women either pregnant or breast feeding